Most KTR were on triple therapy (89.1%), and 79.1% receivedcalcineurin inhibitors (Table 2).Prescription of medications for CKD-related complications was similar betweengroups, except for erythropoietin, more common in KTR (28.7% vs.3.96%, p < 0.001), and cholecalciferol, more common in NT-PDP(48.5% vs. 2.97%, p < 0.001) (Table 1). This evidence concerns the gene EPO and chronic kidney disease.